Table 1 Demographics and clinical characteristics of population at baseline
Tocilizumab | Placebo | |
|---|---|---|
Male sex, n (%) | 205 (69.7) | 101 (70.1) |
Age [yr], Median (P25, P75) | 62 (51, 70) | 61 (53.5, 70) |
Mechanical Ventilation at baseline = Yes, n (%) | 110 (37.4) | 55 (38.2) |
Extracorporeal membrane oxygenation (ECMO) at baseline = Yes, n (%) | 10 (3.4) | 8 (5.6) |
Intensive Care Unit (ICU) Stay at baseline = Yes, n (%) | 167 (56.8) | 80 (55.6) |
Days from first COVID-19 symptom at baseline, Median (P25, P75) | 11 (7.5, 15) | 10 (7, 14) |
Antiviral Treatment at baseline = Yes, n (%) | 71 (24.1) | 42 (29.2) |
Coexisting illness, n (%) | ||
≥ 1 Diagnosis | 231 (78.6) | 124 (86.1) |
Obesity | 63 (21.4) | 27 (18.8) |
Diabetes | 105 (35.7) | 62 (43.1) |
Cardiovascular impairment | 88 (29.9) | 35 (24.3) |
Hypertension | 178 (60.5) | 94 (65.3) |
Hepatic impairment | 6 (2.0) | 2 (1.4) |
Chronic lung disease | 49 (16.7) | 22 (15.3) |